Nwam LLC Purchases 5,901 Shares of Insmed, Inc. $INSM

Nwam LLC increased its position in shares of Insmed, Inc. (NASDAQ:INSM) by 15.1% in the first quarter, Holdings Channel.com reports. The firm owned 44,883 shares of the biopharmaceutical company’s stock after purchasing an additional 5,901 shares during the quarter. Nwam LLC’s holdings in Insmed were worth $7,339,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in Insmed in the 4th quarter worth about $506,625,000. RTW Investments LP grew its stake in shares of Insmed by 57.0% during the fourth quarter. RTW Investments LP now owns 4,842,879 shares of the biopharmaceutical company’s stock valued at $842,855,000 after buying an additional 1,758,321 shares during the last quarter. Orbis Allan Gray Ltd bought a new position in shares of Insmed during the second quarter valued at approximately $153,389,000. State Street Corp raised its holdings in shares of Insmed by 30.6% in the fourth quarter. State Street Corp now owns 5,201,744 shares of the biopharmaceutical company’s stock worth $905,312,000 after buying an additional 1,217,390 shares during the period. Finally, Vanguard Group Inc. raised its holdings in shares of Insmed by 5.7% in the fourth quarter. Vanguard Group Inc. now owns 21,076,344 shares of the biopharmaceutical company’s stock worth $3,668,127,000 after buying an additional 1,140,524 shares during the period.

Insmed Stock Performance

Insmed stock opened at $110.11 on Wednesday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 4.10 and a current ratio of 4.47. The company has a market capitalization of $23.87 billion, a PE ratio of -19.15 and a beta of 0.78. The company has a 50 day moving average price of $106.08 and a 200-day moving average price of $137.07. Insmed, Inc. has a fifty-two week low of $90.39 and a fifty-two week high of $212.75.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.14. The company had revenue of $305.96 million for the quarter, compared to analysts’ expectations of $300.81 million. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.Insmed’s revenue was up 229.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.42) earnings per share. As a group, equities analysts forecast that Insmed, Inc. will post -2.55 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on INSM. Stifel Nicolaus raised their price target on Insmed from $205.00 to $208.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. Guggenheim reaffirmed a “buy” rating and issued a $207.00 price objective on shares of Insmed in a research report on Friday, July 10th. JPMorgan Chase & Co. reduced their target price on Insmed from $180.00 to $179.00 and set an “overweight” rating on the stock in a research note on Monday, June 8th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a research report on Wednesday, June 10th. Finally, Barclays boosted their target price on shares of Insmed from $231.00 to $237.00 and gave the company an “overweight” rating in a research note on Wednesday, April 1st. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $211.00.

Insider Transactions at Insmed

In related news, CFO Sara Bonstein sold 2,404 shares of Insmed stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total value of $245,857.08. Following the completion of the sale, the chief financial officer directly owned 69,082 shares in the company, valued at $7,065,016.14. The trade was a 3.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO William Lewis sold 10,699 shares of Insmed stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $117.40, for a total value of $1,256,062.60. Following the completion of the sale, the chief executive officer owned 259,058 shares of the company’s stock, valued at $30,413,409.20. The trade was a 3.97% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 65,289 shares of company stock valued at $7,334,073 over the last 90 days. 2.10% of the stock is owned by corporate insiders.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.